Have a personal or library account? Click to login
New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods Cover

New strategies for the control of infectious and parasitic diseases in blood donors: the impact of pathogen inactivation methods

By: Luca Galli and  Fabrizio Bruschi  
Open Access
|Apr 2020

Figures & Tables

Figure 1

Amotosalen/UVA technology mechanism of action. Photoactive compound targets nucleic acids; UVA illumination activates photoactive compuond causing permanent cross-links between the double-stranded chains and blocks the replication of DNA and RNA. From: http://www.intercept-usa.com.
Amotosalen/UVA technology mechanism of action. Photoactive compound targets nucleic acids; UVA illumination activates photoactive compuond causing permanent cross-links between the double-stranded chains and blocks the replication of DNA and RNA. From: http://www.intercept-usa.com.

Figure 2

Mirasol mechanism of action. From Ref. (77), with permission.
Mirasol mechanism of action. From Ref. (77), with permission.

Figure 3

Reduction of various bacterial species when treated with Mirasol PRT System. From Ref (77), with permission.
Reduction of various bacterial species when treated with Mirasol PRT System. From Ref (77), with permission.

Reduction of infectious disease agent logs induced by different PI technologiesResults are expressed as > number indicate that the pathogen concentrations was reduced to the limit of detection of the assay

PathogenAmotosalen/UVARiboflavin/UVUVCAmustaline-GSH
HBVEnveloped virus>5.5 (66)2.5 (76)na

not available.

>5.1 (105)
HCVEnveloped virus>4.5 (66)3.2 (76)>4.9 (103)na

not available.

HIV (cell free) latentEnveloped virus>6.2 (66)>4.5 (76)1.4 (90)>6.5 (92)
HIV (cell-associated) activeEnveloped virus>6.1 (66)>5.9 (76)na

not available.

>5.9 (91)
CMVEnveloped virus>5.9 (66)2.1 (76)na

not available.

>6 (105)
WNVEnveloped virus>6.0 (66)>5.1 (76)3.4 - 4 (85)> 6.0 (93)
CHIKVEnveloped virus>6.9 (31)2.1 - 4 (83)6.34 (86)> 6.78 (31)
Influenza A virusEnveloped virus>5.9 (66)>5 (76)na

not available.

na

not available.

HAVNonenveloped virus0.6 (98)1.8 (76)4.2 (87)na

not available.

Parvovirus B19Nonenveloped virus3.5-5.0 (99)>5 (76)5.4 (31)na

not available.

Zika VirusEnveloped virus> 6 (68)na

not available.

5.7 (104)5.99 (94)
Dengue VirusEnveloped virus> 4.3 (100)1.8 (101)>4.6 (86)6.61 (106)
Staphylococcus aureusBacteria (Gram positive)>6.6 (67)4.8 (6)>4.4 (88)5.1 (91)
Staphylococus epidermidisBacteria (Gram positive)>6.6 (67)4.2 (102)4.6 (88)> 6.9 (92)
Pseudomonas aeruginosaBacteria (Gram negative)4.5 (67)4.5 (6)4.9 (84)4.5 (92)
Escherichia coliBacteria negative) (Gram>6.4 (67)4.4 (102)7.3 (88)>6.7 (91)
Serratia marcescensBacteria (Gram negative)> 6.7 (67)4 (6)> 5 (88)5.1 (91)
Yersinia enterocoliticaBacteria (Gram negative)> 5.9 (66)3.3 (6)na

not available.

>6.8 (93)
Trypanosoma cruziProtozoa>5.3 (66)>5 (76)na

not available.

> 5.4 (93)
Plasmodium sppProtozoa>6 (66)>3.2 (76)na

not available.

> 6.8 (93)
Babesia sppProtozoa> 5.3 (66)>4 (76)> 5 (89)>5.5 (93)
Language: English
Page range: 53 - 66
Published on: Apr 30, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Luca Galli, Fabrizio Bruschi, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.